

First Canadian patent approval for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has received its first Notice of Allowance from the The Canadian Intellectual Property Office (CIPO).

The patent, entitled “*Surgical kit for cartilage repair comprising implant and a set of tools*”, has a focus on the company’s individualised Episealer® Femoral Twin joint implant and its design.

“The first approval in a for us new country is an important step. We are looking forward to future activities in North America”, comments Pål Ryfors, CEO, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel: +46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s µFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.55 CEST on 29 August 2018.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel: +46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com